According to The Fly, cowen & Co. analyst Ritu Baral maintained a Buy rating on GlycoMimetics (NASDAQ: GLYC) yesterday. The company’s shares opened today at $12.09, close to its 52-week low of $10.56.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.2% and a 46.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on GlycoMimetics is a Moderate Buy with an average price target of $24.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.05 and a one-year low of $10.56. Currently, GlycoMimetics has an average volume of 268.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates.
